Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer? | Zendy

Maria A. Velez | Zendy; Timothy F. Burns | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Is the game over for PD-1 inhibitors in EGFR mutant non-small cell lung cancer?

Author(s) -

Maria A. Velez,

Timothy F. Burns

Publication year - 2019

Publication title -

translational lung cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.474

H-Index - 41

eISSN - 2226-4477

pISSN - 2218-6751

DOI - 10.21037/tlcr.2019.04.09

Subject(s) - pembrolizumab , medicine , lung cancer , epidermal growth factor receptor , cancer research , tyrosine kinase , pd l1 , mutant , egfr inhibitors , mutation , cancer , oncology , receptor , immunotherapy , biology , gene , genetics

The immune checkpoint inhibitor pembrolizumab, has been shown to be efficacious and to have significant and durable antitumor activity in a subset of patients with advanced non-small cell lung cancer (NSCLC). Most notably in NSCLC with high expression of the programmed death ligand-1 (PD-L1). Similarly, there is abundant data to support the use of epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line therapy in patients whose tumors harbor EGFR mutations (1).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research